Cargando…

Estimating progression-free survival in patients with glioblastoma using routinely collected data

Glioblastoma (GBM) represents 80% of all primary malignant brain tumours in adults. Prognosis is poor, and there is a clear correlation between disease progression and deterioration in functional status. In this pilot study we assess whether we can estimate disease progression and progression free s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelly, Charlotte, Majewska, Paulina, Ioannidis, Stefanos, Raza, Muhammad Hasan, Williams, Matt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700233/ https://www.ncbi.nlm.nih.gov/pubmed/28956223 http://dx.doi.org/10.1007/s11060-017-2619-1

Ejemplares similares

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Glioblastoma: A Retrospective Analysis of the Role of the Maximal Surgical Resection on Overall Survival and Progression Free Survival
por: Polonara, Gabriele, et al.
Publicado: (2023)

Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey
por: Hemkens, Lars G, et al.
Publicado: (2016)

Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival
por: Gandhi, Puneet, et al.
Publicado: (2017)

Routinely collected data for randomized trials: promises, barriers, and implications
por: Mc Cord, Kimberly A., et al.
Publicado: (2018)

New method for determining breast cancer recurrence-free survival using routinely collected real-world health data
por: Jung, Hyunmin, et al.
Publicado: (2022)

A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma
por: Wong, Bin Sheng, et al.
Publicado: (2020)

High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma
por: Alves, Bárbara, et al.
Publicado: (2023)

Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach
por: Murphy, Á C, et al.
Publicado: (2013)

Diffusion MRI Characteristics After Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma
por: Chang, Warren, et al.
Publicado: (2015)

Magnetic resonance spectroscopic correlates of progression free and overall survival in “glioblastoma, IDH-wildtype, WHO grade-4”
por: Sacli-Bilmez, Banu, et al.
Publicado: (2023)

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort
por: Rouyer, Magali, et al.
Publicado: (2019)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Complete and Incomplete Resection for Progressive Glioblastoma Prolongs Post-Progression Survival
por: Behling, Felix, et al.
Publicado: (2022)

Progression-free survival and quality of life in metastatic breast cancer: The patient perspective
por: Mertz, Shirley, et al.
Publicado: (2022)

AKT/GSK3β Signaling in Glioblastoma
por: Majewska, Ewelina, et al.
Publicado: (2016)

Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma
por: Fathi Kazerooni, Anahita, et al.
Publicado: (2020)

Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma
por: Paik, Wooyul, et al.
Publicado: (2016)

Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma
por: Lin, Yi, et al.
Publicado: (2021)

Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide
por: Brawanski, Konstantin R., et al.
Publicado: (2023)

Pre-operative apparent diffusion coefficient values and tumour region volumes as prognostic biomarkers in glioblastoma: correlation and progression-free survival analyses
por: Durand-Muñoz, Coral, et al.
Publicado: (2019)

Estimating discharge dates using routinely collected data: improving the preparedness of parents of preterm infants for discharge home
por: Fleming, Peter J, et al.
Publicado: (2017)

A spatial-mechanistic model to estimate subnational tuberculosis burden with routinely collected data: An application in Brazilian municipalities
por: Chitwood, Melanie H., et al.
Publicado: (2022)

Validating epilepsy diagnoses in routinely collected data
por: Fonferko-Shadrach, Beata, et al.
Publicado: (2017)

Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study
por: Mc Cord, Kimberly A, et al.
Publicado: (2021)

Estimation of Influenza Vaccine Effectiveness from Routine Surveillance Data
por: Kelly, Heath, et al.
Publicado: (2009)

Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma
por: Wach, Johannes, et al.
Publicado: (2021)

Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
por: van Genugten, J. A. B., et al.
Publicado: (2009)

Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
por: Buda-Nowak, Anna, et al.
Publicado: (2017)

Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures
por: Yerukala Sathipati, Srinivasulu, et al.
Publicado: (2016)

Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma
por: Bagley, Stephen J, et al.
Publicado: (2021)

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Kaka, Nagham, et al.
Publicado: (2019)

Protocadherin Gamma C3 (PCDHGC3) Is Strongly Expressed in Glioblastoma and Its High Expression Is Associated with Longer Progression-Free Survival of Patients
por: Feldheim, Jonas, et al.
Publicado: (2022)

Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?
por: Carrillo, Jose A., et al.
Publicado: (2019)

Effect of Study Duration and Outcome Measurement Frequency on Estimates of Change for Longitudinal Cohort Studies in Routinely-Collected Administrative Data
por: Feely, A, et al.
Publicado: (2020)

Impact of a stepwise introduction of smoke-free legislation on the rate of preterm births: analysis of routinely collected birth data
por: Cox, Bianca, et al.
Publicado: (2013)

Bias in progression‐free survival analysis due to intermittent assessment of progression
por: Zeng, Leilei, et al.
Publicado: (2015)

Using routinely collected data to improve immunisation histories
por: Allen, Luke
Publicado: (2013)

Reliability of routinely collected anthropometric measurements in primary care
por: Carsley, Sarah, et al.
Publicado: (2019)

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial
por: Buchroithner, Johanna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j4tqigr5uh8gnl0l2dao23p5gn